Ramon L. Laguarta
Chairman and Chief Executive Officer at PepsiCo
Thank you, Filippo. Good question. Listen, obviously, we're looking at this along with many other positive and negative potential risks for our business, our category. So far, the impact is negligible in our business. Overall, if you take global consumption, there are obviously a lot of question marks with regards to these obesity drugs when it comes to medical testing or scalability of the usage of this or what is the impact really on consumer choices, so a lot of question marks. We continue to believe that all the structural positive trends that we had to our categories remain, and I mentioned -- I referred to that earlier in the conversation. So, we're seeing urbanization as a big driver of adoption of our categories. We're seeing middle-class development. We're seeing lifestyle, and the people snacking to eat, so meals becoming more mini meals and much more unstructured during the day, being a big driver of our categories, both beverages and snacks. So, we're seeing a lot of tailwinds that will continue to drive our categories. Of course, we're observing the growth of these new drugs and its potential impact.
The other thing we're looking at is, is our strategy sound when it comes to portfolio transformation? And everything we've been doing for the last five, six years when it comes to reducing sodium, reducing fat, reducing sugar, reducing the portion control -- the portions of our products, adding some new cooking methods to our snacks, those are all very positive trends that will help us pivot the portfolio if needed in the future. We'll continue to do it obviously where it's one of our key strategic pillars. So, again, negligible impact today. A lot of these structural trends that are in our category I think remain very solid, and even we see them accelerating. And our portfolio strategy we think is very solid when it comes to a potential protection against some of these future developments five, 10 years from now.